Latest News

Title
Abstracts
Programme
21 Sep 2017 Withdrawal of the Application for a Change to the Marketing Authorisation for Nivolumab in EU Cancer Immunology and Immunotherapy
20 Sep 2017 EMA Recommends Granting a Marketing Authorisation for Trastuzumab Biosimilar Breast cancer - Gastrointestinal cancers - Anticancer agents & Biologic therapy
14 Sep 2017 ESMO Press Release: ESMO announces new interim Editor-in-Chief of Annals of Oncology
19 Sep 2017 EMA Recommends Granting a Marketing Authorisation for Niraparib Gynaecologic malignancies - Anticancer agents & Biologic therapy
18 Sep 2017 FDA Approves a Biosimilar to Bevacizumab Anticancer agents & Biologic therapy
Programme
15 Sep 2017 Questionnaire Designed for Adolescent and Young Adults with Cancer Elicits Their Views on Treatment Cancer in Special Situations
14 Sep 2017 Reports on Care Quality for Adolescent and Young Adult Cancer Patients Are Lacking in the Literature Cancer in Special Situations
12 Sep 2017 ESMO 2017: Daily Broadcasts
12 Sep 2017 ESMO 2017 Press Release: Best of ESMO 2017 Congress
12 Sep 2017 ESMO 2017 Press Release: Best Poster at ESMO 2017 Shows Positive Trials Twice as Likely to be Reported in Lay Press
11 Sep 2017 ESMO 2017: Adjuvant Dabrafenib Plus Trametinib Significantly Lowers Risk of Death in Stage III BRAF V600–Mutated Melanoma Melanoma and other skin tumours - Anticancer agents & Biologic therapy
11 Sep 2017 ESMO 2017: Nivolumab Bests Ipilimumab as Adjuvant Therapy in Resected Melanoma Melanoma and other skin tumours - Cancer Immunology and Immunotherapy